Kisspeptin-10 (10 mg vial) dosage protocol

1. Draw 3 mL of bacteriostatic water with a sterile syringe.
2. Inject it slowly down the inside wall of the vial, not onto the powder, to avoid foaming.
3. Swirl or roll the vial gently until the powder dissolves. Do not shake it.
4. Label it with the date and the volume of water, and refrigerate at 2-8 °C (36-46 °F), away from light.

• Reconstitute: add 3 mL of bacteriostatic water for a 3.33 mg/mL solution.
• Amounts in the chart: 100 mcg-200 mcg each time, by subcutaneous injection, once a day.
• Easy measuring: at 3.33 mg/mL, one unit (0.01 mL) on a U-100 insulin syringe holds about 33.3 mcg.
• Storage: freeze-dried, keep it sealed, cold and away from light (frozen for long storage). Once mixed, refrigerate at 2-8 °C and avoid freezing and thawing.

Kisspeptin-10 is the shortest active fragment of kisspeptin, a hormone that triggers the release of GnRH and, through it, LH, FSH and testosterone. It has been given to people only in small physiology studies, is not FDA-approved, and is banned in male athletes by WADA.

• Primary calculation: 10 mg made up to 3 mL equals 3.33 mg/mL.
• Amounts shown: 100 mcg-200 mcg per administration. Reported in the research community. It has not been tested as a schedule in human trials.
• Route and frequency: subcutaneous injection, once a day.
• Evidence ceiling: 11 of the 12 studies with a dose in our library were done in people.
• Regulatory status: Not FDA-approved for any use. WADA: Prohibited at all times in males (S2.2.1, testosterone-stimulating peptides: kisspeptin and its agonist analogues).

A 10 mg vial holds 10,000 mcg of Kisspeptin-10. Adding 3 mL gives 3.33 mg/mL, so one U-100 unit (0.01 mL) holds 33.3 mcg. To get the units for an amount, divide it by 33.3 mcg. The units are a volume mark on the syringe, not a measure of potency.

• 100 mcg: 0.03 mL, or 3 U-100 units.
• 200 mcg: 0.06 mL, or 6 U-100 units.

Vial coverage by mass: 100 full amounts of 100 mcg, 50 full amounts of 200 mcg per vial, before any handling loss.

If a different volume of water is used, every unit figure changes: recalculate with the calculator above.

Kisspeptin-10 has been given to people in carefully monitored hospital research units. These are physiology studies, not treatment trials:

• Healthy men, dose response: intravenous injections raised LH within 30 minutes, with the biggest effect at 1 µg/kg; the highest dose gave a smaller response. A 22.5-hour infusion raised LH and testosterone and made LH pulses more frequent (George 2011).
• Resetting the hormone clock: a single injection in 13 men triggered an immediate LH pulse and delayed the next natural one, as if resetting the GnRH pulse generator (Chan 2011).
• Men and women respond differently: men responded at low doses, but women in the early (follicular) phase of the cycle did not respond even to high doses; women just before ovulation did (Jayasena 2011). A study across the cycle found clear responses in the luteal phase and inconsistent ones in the early follicular phase (Chan 2012).
• Effect of sex hormones in women: the LH response was larger after menopause and absent in women on the combined pill (George 2012).
• Men with type 2 diabetes and low testosterone: in five men, an 11-hour infusion raised LH, LH pulse frequency and testosterone (George 2013).
• Compared with GnRH and kisspeptin-54: at the doses tested, kisspeptin-10 and kisspeptin-54 raised LH and FSH similarly, and GnRH itself was more potent than either (Jayasena 2015).
• Testing GnRH function: people with congenital GnRH deficiency did not respond, while a man whose condition had reversed did (Chan 2014). In 16 young people with delayed puberty, the response predicted who later went through puberty (Chan 2020). The abstracts of these two studies say "kisspeptin" without naming the form; the same Boston group used kisspeptin-10 in its other studies.
• Longer use: in healthy men, daily 8-hour infusions under the skin kept LH, FSH and testosterone raised for 12 days, but continuous infusion for 5 days lost its effect on LH and FSH (Yeung 2026).

Verdict: there is consistent evidence, from three independent groups, that kisspeptin-10 raises LH and, in men, testosterone within hours. The studies are small, short and done under medical supervision, with intravenous or carefully controlled infusions. No trial has tested whether it improves any health outcome, and long-term effects are unknown.

Doses used in human studies

• George JT 2011: Intravenous boluses of 0.01 to 3.0 µg/kg (and vehicle); infusions of 4 µg/kg per hour for 22.5 hours and 1.5 µg/kg per hour (Intravenous bolus and intravenous infusion; Single doses and infusions of up to 22.5 hours)
• Chan YM 2011: Single intravenous bolus of kisspeptin 112-121 (kisspeptin-10). Amount not given in the abstract; see the paper (Intravenous bolus)
• Jayasena CN 2011: In men, intravenous boluses with effects from 0.3 nmol/kg (LH) and 1.0 nmol/kg (FSH). In women, up to 10 nmol/kg intravenous bolus, 32 nmol/kg subcutaneous bolus or 720 pmol/kg per minute intravenous infusion (Intravenous bolus, subcutaneous bolus and intravenous infusion)
• George JT 2012: 0.3 µg/kg intravenous bolus (Intravenous bolus; Hormones followed for 60 minutes after the dose)
• Chan YM 2012: Kisspeptin 112-121 (kisspeptin-10) 0.24 nmol/kg intravenous bolus; 0.72 nmol/kg in four additional women (Intravenous bolus)
• George JT 2013: 0.3 µg/kg intravenous bolus; 4 µg/kg per hour intravenous infusion for 11 hours (Intravenous bolus and intravenous infusion; Single bolus; 11-hour infusion)
• Chan YM 2014: Kisspeptin 0.24 nmol/kg intravenous bolus, before and after 6 days of GnRH (25 ng/kg every 2 hours) (Intravenous bolus)
• Jayasena CN 2015: 0.1, 0.3 and 1.0 nmol/kg per hour for 3 hours, for each of kisspeptin-10, kisspeptin-54 and GnRH, plus vehicle (Intravenous infusion; 3-hour infusions on separate days at least a week apart)
• Yeung AC 2026: Acute 8-hour infusions of 1.25 to 10.0 nmol/kg per hour; continuous 180 nmol/h for 5 days; daily 8-hour infusions of 150 nmol/h for 12 days; 1 nmol/kg bolus at the end (Subcutaneous infusion; Up to 12 days)

Every study dose, including animal and cell studies, is in the Kisspeptin-10 dose table.

The human studies were short, involved small numbers of volunteers and were run in hospital research units. They were designed to measure hormones, not to assess safety, so side effects and long-term effects in people are largely unknown.

• Hormonal disruption: it acts at the top of the reproductive hormone chain. Constant exposure blunted the LH and FSH response within days in healthy men (Yeung 2026), and responses depend on sex, cycle phase and other hormones, so effects outside a supervised study are hard to predict.
• Unpredictable response in women: in some women it had no measurable effect at all, depending on the phase of the menstrual cycle (Jayasena 2011).
• Product quality: an anti-doping laboratory that tested a black-market vial found no unexpected impurities but more degradation than in a reference standard; the peptide is also prone to oxidation (Colpaert 2024). Products sold online are not checked by any regulator.
• Sport: prohibited at all times for male athletes under WADA class S2.2.1, and laboratories have validated urine tests for it (Colpaert 2024).

• FDA: Not FDA-approved for any use.
• WADA: Prohibited at all times in males (S2.2.1, testosterone-stimulating peptides: kisspeptin and its agonist analogues).
• Evidence limits: reported use is not evidence that a schedule works or is safe. Animal doses do not convert to people, and research products are not made or checked for use in people.
• Status checked on: Oct 26, 2026.